GlassScriptPhysician profile
Robert L Duhaney
NPI 1922151588
$1,875.03
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $644 · 2021: $152 · 2024: $31.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $422.37 | 2019-2020 | |
| Novo Nordisk INC | $272.63 | 2019-2021 | |
| Amgen INC. | $272.06 | 2019-2020 | |
| Allergan, INC. | $129.44 | 2019-2020 | |
| Astellas Pharma US INC | $64.68 | 2019 | |
| Merck Sharp & Dohme LLC | $63.49 | 2019-2020 | |
| Lilly USA, LLC | $57.50 | 2020-2021 | |
| Abbvie INC. | $55.71 | 2021 | |
| Amarin Pharma, INC. | $55.47 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $54.35 | 2019-2021 | |
| Eisai INC. | $52.32 | 2020 | |
| Shire North American Group INC | $49.23 | 2019 | |
| Antares Pharma, INC. | $45.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.29 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $31.90 | 2024 | Daxxify |
| Vivus LLC | $30.52 | 2019 | |
| Organon LLC | $21.66 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.81 | 2020 | |
| Ironwood Pharmaceuticals, INC | $16.95 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.80 | 2021 | |
| Pfizer INC. | $14.87 | 2020 | |
| Sunovion Pharmaceuticals INC. | $14.86 | 2019 | |
| Currax Pharmaceuticals LLC | $14.20 | 2020 | |
| Scilex Pharmaceuticals INC. | $14.10 | 2019 | |
| Glaxosmithkline, LLC. | $13.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Duhaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.